4-(吡啶-4-基甲氧基)苯胺 | 105350-42-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(吡啶-4-基甲氧基)苯胺
• 英文名称: 4-(4-pyridinylmethoxy)aniline
• 英文别名: 4-(4-pyridylmethoxy)aniline；4-(pyridin-4-ylmethoxy)aniline；4-[(pyridine-4-yl)methoxy]aniline；4-(pyridin-4-ylmethoxy)-phenylamine
• CAS: 105350-42-3
• 化学式: C₁₂H₁₂N₂O
• mdl: MFCD04971041
• 分子量: 200.24
• InChiKey: GYLBVAPFPIKDNV-UHFFFAOYSA-N

物化性质

• 沸点：
  390.1±22.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(吡啶-4-基甲氧基)苯胺 在 potassium carbonate 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 33.0h， 生成 1-[4-(4-pyridylmethoxy)phenyl]imidazolidine-2,4-dione
  参考文献：
  名称：

  Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin

  摘要：

  In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is that the interaction between the plasmin inhibitors and key subsites in plasmin can be controlled by a spacer like hydantoin. The application of the novel chemotype is demonstrated by 1n and provides further evidence on the importance of hydantoin as the spacer. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.002
• 作为产物：
  描述：

  4-(4'-pyridylmethoxy)acetanilide 在 盐酸 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 4-(吡啶-4-基甲氧基)苯胺
  参考文献：
  名称：

  2-quinolinyl methoxy compounds, medical uses and intermediates therefor

  摘要：

  本发明涉及以下结构的化合物：##STR1## 其中式中 X 代表 O、S、##STR2## R.sub.1 和 R.sub.2 可以相同也可以不同，代表氢、直链或支链、饱和或不饱和、未取代或取代的 C.sub.1-C.sub.8-烷基、芳基或 ar-C.sub.1-C.sub.4-烷基，芳基和 ar 均为未取代或取代的苯基；R.sub.3、R.sub.4、R.sub.5 和 R.sub.6 可以相同也可以不同，代表氢、卤素、伪卤素、氰基、硝基、氨基、羧基、羟基、烷基、烷氧基；或者 R.sub.5 和 R.sub.6 形成与吡啶环融合的芳香环，该芳香环可以被取代；但要求 R.sub.1 和 R.sub.2 不能同时为氢，当 R.sub.5 和 R.sub.6 都是氯且 R.sub.1 是氢时，R.sub.2 不能是 n-丙基；以及其盐和生物可逆衍生物。式中的化合物在人类和兽医治疗中具有特异的5-脂氧酶抑制作用。

  公开号：

  US05157039A1

文献信息

• Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-<i>d</i>]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family
  作者：Jeff B. Smaill、Andrea J. Gonzales、Julie A. Spicer、Helen Lee、Jessica E. Reed、Karen Sexton、Irene W. Althaus、Tong Zhu、Shannon L. Black、Adrian Blaser、William A. Denny、Paul A. Ellis、Stephen Fakhoury、Patricia J. Harvey、Ken Hook、Florence O. J. McCarthy、Brian D. Palmer、Freddy Rivault、Kevin Schlosser、Teresa Ellis、Andrew M. Thompson、Erin Trachet、R. Thomas Winters、Haile Tecle、Alexander Bridges

  DOI：10.1021/acs.jmedchem.6b00883

  日期：2016.9.8

  potency was investigated. Several anilines were identified as providing potent, reversible pan-erbB inhibition. Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo. Quinazoline 54 and pyrido[3,4-d]pyrimidine 71 were identified as clearly superior to canertinib. Both compounds possess a piperidinyl crotonamide Michael acceptor

  确定了一系列不可逆的pan-erbB抑制剂canertinib的基于喹唑啉和吡啶并[3,4- d ]嘧啶的类似物，确定了与erbB1，erbB2和erbB4抑制相关的构效关系。测定带有环胺的巴豆酰胺可在肝微粒体和肝细胞测定中快速抑制细胞erbB1自磷酸化并具有良好的代谢稳定性。研究了4-苯胺基取代对pan-erbB抑制效能的影响。几种苯胺被鉴定为提供有效的，可逆的pan-erbB抑制作用。具有已知7位取代基的最佳4位和6位取代基为体内药效学测试提供了首选的不可逆抑制剂。喹唑啉54和吡啶并[3,4- d ]嘧啶确定有71例明显优于canertinib。两种化合物均具有哌啶基巴豆酰胺迈克尔受体和3-氯-4-氟苯胺，分别表明它们分别为优化的6-和4-取代基。化合物54和71在三个物种中的药代动力学比较选择了化合物54作为优选的候选物。已为化合物54（PF-00299804）命名为dacomitinib，目前正在临床评估中。
• Pyridyl and quinoline derivatives
  申请人：Leo Pharmaceutical Products Ltd.

  公开号：US04826987A1

  公开（公告）日：1989-05-02

  The present invention relates to compounds of formula I ##STR1## in which formula I X stands for O, S, ##STR2## R.sub.1 and R.sub.2 which can be the same or different stand for hydrogen, straight or branched, saturated or unsaturated, unsubstituted or substituted C.sub.1 -C.sub.8 -alkyl, or for ar-C.sub.1 -C.sub.4 -alkyl, aryl and ar being unsubstituted or substituted phenyl; R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are the same or different and stand for hydrogen, halogen, pseudo halogen, cyano, nitro, amino, carboxy, hydroxy, alkyl, alkoxy; or R.sub.5 and R.sub.6 form an aromatic ring which is fused to the pyridyl ring, and which aromatic ring may substituted; provided that R.sub.1 and R.sub.2 cannot be hydrogen at the same time, and provided that when R.sub.5 and R.sub.6 both are chlorine and R.sub.1 is hydrogen, then R.sub.2 cannot be n-propyl; and salts and bioreversible derivatives thereof. The compounds of formula I are useful in the human and veterinary therapy, as they exert specific 5-lipoxygenase inhibition.

  本发明涉及以下式的化合物##STR1## 在该式中，X代表O、S、##STR2## R.sub.1和R.sub.2可以相同也可以不同，代表氢、直链或支链、饱和或不饱和、未取代或取代的C.sub.1-C.sub.8-烷基，或者代表ar-C.sub.1-C.sub.4-烷基，aryl和ar代表未取代或取代的苯基；R.sub.3、R.sub.4、R.sub.5和R.sub.6可以相同也可以不同，代表氢、卤素、伪卤素、氰基、硝基、氨基、羧基、羟基、烷基、烷氧基；或者R.sub.5和R.sub.6形成与吡啶环融合的芳香环，该芳香环可以被取代；但是R.sub.1和R.sub.2不能同时是氢，当R.sub.5和R.sub.6都是氯且R.sub.1是氢时，R.sub.2不能是正丙基；以及其盐和生物可逆衍生物。式I的化合物在人类和兽医疗法中是有用的，因为它们具有特异的5-脂氧酶抑制作用。
• [EN] TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY<br/>[FR] DÉRIVÉS TRIAZOLES À ACTIVITÉ ANTIFONGIQUE
  申请人：KING S COLLEGE LONDON

  公开号：WO2021156636A1

  公开（公告）日：2021-08-12

  Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, Q2, L1 and n are as defined herein. The compounds have antifungal properties and are useful in the treatment of fungal infections, including infections that are resistant to conventions anti-fungal agents. Q1 is selected from: (Formulae Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij and Ik) wherein * indicates the point of attachment to L1.

  揭示了公式(I)的化合物及其药学上可接受的盐，其中R1、R2、Q2、L1和n的定义如本文所述。这些化合物具有抗真菌性能，并可用于治疗真菌感染，包括对传统抗真菌药物产生耐药性的感染。Q1选自:(公式Ia、Ib、Ic、Id、Ie、If、Ig、Ih、Ii、Ij和Ik)，其中*表示与L1的连接点。
• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20090041786A1

  公开（公告）日：2009-02-12

  The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

  这项发明涵盖了具有I-V公式的化合物以及使用这些化合物在治疗需要调节JAK通路或抑制JAK激酶，特别是JAK3的情况下可能具有治疗作用的组合物和方法。
• Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
  申请人：Floersheimer Andreas

  公开号：US20060128734A1

  公开（公告）日：2006-06-15

  The invention relates to the use of diaryl urea derivatives in the treatment of protein kinase dependent diseases or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diaryl urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising diaryl urea derivatives for the treatment of said diseases, diaryl urea derivatives for use in the treatment of said diseases, novel diaryl urea derivatives, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.

  本发明涉及在蛋白激酶依赖性疾病的治疗中使用二芳基脲衍生物或用于制造用于治疗该类疾病的药物组合物，二芳基脲衍生物在治疗该类疾病中的使用方法，包含二芳基脲衍生物的制备用于治疗该类疾病的制药制剂，用于治疗该类疾病的二芳基脲衍生物，新型的二芳基脲衍生物，包含这些新型二芳基脲衍生物的制药制剂，制造这些新型二芳基脲衍生物的方法，上述新型二芳基脲衍生物的使用或使用方法，以及/或这些新型二芳基脲衍生物用于治疗动物或人体。